AACP
IRWD icon

Advantage Alpha Capital Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Advantage Alpha Capital Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-118,514
Closed -$773K – 181
2024
Q2 		$773K Sell
118,514
-12,452
-10% -$88.1K 0.17% 92
2024
Q1 		$1.14M Buy
130,966
+5,261
+4% +$63.8K 0.21% 92
2023
Q4 		$1.44M Buy
+125,705
New +$1.24M 0.27% 89

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advantage Alpha Capital Partners's IRWD Position: Q3 2024 in Review

Advantage Alpha Capital Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2024, closing a stake of 118,514 shares — an estimated $773K sold.

Advantage Alpha Capital Partners first reported a position in IRWD in Q4 2023 and held it in 3 quarters. The position peaked at $1.44M in Q4 2023. 221 funds tracked by Wall St. Rank hold IRWD as of Q3 2024.

  • Advantage Alpha Capital Partners reported no remaining Ironwood Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 118,514 Ironwood Pharmaceuticals shares in Q3 2024, an estimated $773K.
  • Advantage Alpha Capital Partners first reported a position in Ironwood Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Ironwood Pharmaceuticals position peaked at $1.44M in Q4 2023.
  • 221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2024, filed 13 Nov 2024.